Literature DB >> 2412784

The use of neurometrics in the study of patients with cerebral ischaemia.

E J Jonkman, D C Poortvliet, M M Veering, A W De Weerd, E R John.   

Abstract

The 'neurometric' method, as developed by John, was used for the study of patients with one-sided supratentorial ischaemia. The results of a reference group of 64 normal volunteers were compared with those of a group of 94 patients. This patient group included 54 patients with permanent neurological deficit (completed stroke or partial non-progressive stroke) and 40 patients with transient neurological symptoms (reversible ischaemic neurological deficit or transient ischaemic attacks). In 90% of all patients the neurometric method indicated that the EEG had to be considered as abnormal (compared with 3% of false positives in the reference group). A significant overall asymmetry was found in 82% of all patients compared with 2% in the reference group. During the follow-up period of 3 months there was a significant improvement of the EEG (as indicated by 3 neurometric parameters) as well as an improvement in clinical condition. In 57.5% of the EEGs, both the neurometric score and the visual assessment of the EEG indicated that some abnormality was present. In 6.6% of the cases both methods failed to indicate any abnormality. In 34.0% the neurometrics method revealed an abnormality in the EEG which was not found by visual assessment. In only 1.9% of the patients did visual assessment suggest abnormalities which could not be confirmed by neurometrics. In the group of EEGs which were considered as normal by visual assessment, the neurometrics method revealed abnormalities in 84%. The neurometric method is at the moment the most sensitive approach for detecting abnormalities in the EEG of patients with unilateral cerebral ischaemia. However, the method seems not very accurate for lateralization or localization of the lesions.

Entities:  

Mesh:

Year:  1985        PMID: 2412784     DOI: 10.1016/0013-4694(85)91023-5

Source DB:  PubMed          Journal:  Electroencephalogr Clin Neurophysiol        ISSN: 0013-4694


  9 in total

Review 1.  On the controversies about clinical use of EEG brain mapping.

Authors:  M R Nuwer
Journal:  Brain Topogr       Date:  1990       Impact factor: 3.020

2.  The EEG mapping in the evaluation of patients with late onset epilepsy.

Authors:  C Logar
Journal:  Brain Topogr       Date:  1992       Impact factor: 3.020

3.  Quantitative EEG analysis in clinical settings.

Authors:  M R Nuwer
Journal:  Brain Topogr       Date:  1996       Impact factor: 3.020

4.  Quantitative topographic electrophysiology and functional neurologic status in right middle cerebral artery infarction.

Authors:  K D Pool; T Finitzo; C T Hong
Journal:  Brain Topogr       Date:  1990       Impact factor: 3.020

5.  Subtyping of psychiatric patients by cluster analysis of QEEG.

Authors:  E R John; L S Prichep; M Almas
Journal:  Brain Topogr       Date:  1992       Impact factor: 3.020

6.  QEEG profiles of psychiatric disorders.

Authors:  L S Prichep; E R John
Journal:  Brain Topogr       Date:  1992       Impact factor: 3.020

7.  Neurometrics in cerebral ischemia and uremic encephalopathy.

Authors:  J Jonkman; A W de Weerd; D C Poortvliet; R J Veldhuizen; H van Duijn; C A Rozeman; M Laman
Journal:  Brain Topogr       Date:  1992       Impact factor: 3.020

8.  Neuroplastic effects of combined computerized physical and cognitive training in elderly individuals at risk for dementia: an eLORETA controlled study on resting states.

Authors:  Charis Styliadis; Panagiotis Kartsidis; Evangelos Paraskevopoulos; Andreas A Ioannides; Panagiotis D Bamidis
Journal:  Neural Plast       Date:  2015-04-07       Impact factor: 3.599

9.  Comparison of low resolution electromagnetic tomography imaging between subjects with mild and severe obstructive sleep apnea syndrome: a preliminary study.

Authors:  Hyun-Kwon Lee; Doo-Heum Park; Hyun-Sil Shin; Seok-Chan Hong
Journal:  Psychiatry Investig       Date:  2008-03-31       Impact factor: 2.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.